CEVR
@tuftscevr.bsky.social
Center for the Evaluation of Value and Risk in Health at Medical Center. Posts and reposts are not endorsements.
https://cevr.tuftsmedicalcenter.org/
https://cevr.tuftsmedicalcenter.org/
How are pharma #HEOR teams informing industry responses to developments like the #IRA, state #PDABs, and rules for sharing economic evidence with payers?
Read CEVR’s report exploring the results of our new national survey of industry HEOR leaders to find out: tinyurl.com/ywjsntyy
Read CEVR’s report exploring the results of our new national survey of industry HEOR leaders to find out: tinyurl.com/ywjsntyy
The Tufts-CEVR HEOR Leaders Survey: Health Policy Challenges and Opportunities - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
January 21, 2026 at 1:35 PM
How are pharma #HEOR teams informing industry responses to developments like the #IRA, state #PDABs, and rules for sharing economic evidence with payers?
Read CEVR’s report exploring the results of our new national survey of industry HEOR leaders to find out: tinyurl.com/ywjsntyy
Read CEVR’s report exploring the results of our new national survey of industry HEOR leaders to find out: tinyurl.com/ywjsntyy
Grad students: get a head start on summer by applying for our virtual CEA Registry fellowship. Learn more and apply today: cevr.tuftsmedicalcenter.org/news/2026-re...
#internships #fellowship #research #healthecon
@pattysynnott.bsky.social
#internships #fellowship #research #healthecon
@pattysynnott.bsky.social
cevr.tuftsmedicalcenter.org
January 15, 2026 at 7:18 PM
Grad students: get a head start on summer by applying for our virtual CEA Registry fellowship. Learn more and apply today: cevr.tuftsmedicalcenter.org/news/2026-re...
#internships #fellowship #research #healthecon
@pattysynnott.bsky.social
#internships #fellowship #research #healthecon
@pattysynnott.bsky.social
⏰ One week left to submit nominations for Tufts-CEVR's 2025 CEA Paper of the Year Award. Don't miss the chance to have your work recognized!
Did you publish a #CEA in 2025? Applications are now open for the 8th annual Tufts-CEVR CEA Paper of the Year Award.
Est. application time: <5 mins
Award: $500
Due: January 15th: forms.gle/hiPo3nYSE8rV...
#HEOR #healthecon #HTA
Est. application time: <5 mins
Award: $500
Due: January 15th: forms.gle/hiPo3nYSE8rV...
#HEOR #healthecon #HTA
Tufts-CEVR’s 8th Annual Cost-Effectiveness Analysis Paper of the Year Award
The submission deadline is January 15th, 2026. Click next to proceed.
forms.gle
January 8, 2026 at 8:03 PM
⏰ One week left to submit nominations for Tufts-CEVR's 2025 CEA Paper of the Year Award. Don't miss the chance to have your work recognized!
The Tufts-CEVR CEA Registry’s search function can save weeks of effort on lit reviews. Hear how Tara Lavelle used it for a study on vaccine spillover effects.
Access is free for #ISPOR members who are students or who are academic/gov’t researchers in LMICs.
More at cear.tuftsmedicalcenter.org
Access is free for #ISPOR members who are students or who are academic/gov’t researchers in LMICs.
More at cear.tuftsmedicalcenter.org
January 7, 2026 at 7:09 PM
The Tufts-CEVR CEA Registry’s search function can save weeks of effort on lit reviews. Hear how Tara Lavelle used it for a study on vaccine spillover effects.
Access is free for #ISPOR members who are students or who are academic/gov’t researchers in LMICs.
More at cear.tuftsmedicalcenter.org
Access is free for #ISPOR members who are students or who are academic/gov’t researchers in LMICs.
More at cear.tuftsmedicalcenter.org
CEVR’s Tara Lavelle: Tufts-CEVR’s CEA Registry is a powerful, tool that can inform evidence-based health benefit design, new research proposals, and judgments on the value of health care interventions.
More at cear.tuftsmedicalcenter.org
More at cear.tuftsmedicalcenter.org
December 16, 2025 at 5:56 PM
CEVR’s Tara Lavelle: Tufts-CEVR’s CEA Registry is a powerful, tool that can inform evidence-based health benefit design, new research proposals, and judgments on the value of health care interventions.
More at cear.tuftsmedicalcenter.org
More at cear.tuftsmedicalcenter.org
Conversations about drug pricing/value benefit from launch price transparency. New CEVR research finds that, from 2022-2024, pharma companies disclosed 1/3 of drug launch prices proactively and another 1/3 reactively, suggesting room for improvement.
More at tinyurl.com/dsfjft4k
More at tinyurl.com/dsfjft4k
Communication of Launch Prices by Drug Companies, 2022-2024 | AJMC
Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.
tinyurl.com
December 15, 2025 at 2:25 PM
Conversations about drug pricing/value benefit from launch price transparency. New CEVR research finds that, from 2022-2024, pharma companies disclosed 1/3 of drug launch prices proactively and another 1/3 reactively, suggesting room for improvement.
More at tinyurl.com/dsfjft4k
More at tinyurl.com/dsfjft4k
Do US health plans clearly explain how patients can start and stay on neuromuscular disease (NMD) therapies? New CEVR research suggests that they often do not.
Read more about payer transparency/restrictiveness across several NMDs, including #DMD, #SMA, #ALS, and more.
tinyurl.com/mr2cxc52
Read more about payer transparency/restrictiveness across several NMDs, including #DMD, #SMA, #ALS, and more.
tinyurl.com/mr2cxc52
U.S. health plan coverage of Neuromuscular Disease Therapies: An assessment of policy availability and restrictions - A Alex Levine, Julia A Rucker, Alex Cockerham, Joel Cartner,
James D Chambers, 20...
Background: Health plan policies managing neuromuscular disease (NMD) therapies may impose burdensome requirements on patients and providers. While prior resear...
tinyurl.com
December 11, 2025 at 6:17 PM
Do US health plans clearly explain how patients can start and stay on neuromuscular disease (NMD) therapies? New CEVR research suggests that they often do not.
Read more about payer transparency/restrictiveness across several NMDs, including #DMD, #SMA, #ALS, and more.
tinyurl.com/mr2cxc52
Read more about payer transparency/restrictiveness across several NMDs, including #DMD, #SMA, #ALS, and more.
tinyurl.com/mr2cxc52
What is the outlook for US payer coverage of specialty drugs in 2026? CEVR’s James Chambers will share insights from our SPEC database during a “can’t miss” webinar next week.
When: December 18, 12-12:30 pm ET
Register at tinyurl.com/56959f62
When: December 18, 12-12:30 pm ET
Register at tinyurl.com/56959f62
December 11, 2025 at 4:34 PM
What is the outlook for US payer coverage of specialty drugs in 2026? CEVR’s James Chambers will share insights from our SPEC database during a “can’t miss” webinar next week.
When: December 18, 12-12:30 pm ET
Register at tinyurl.com/56959f62
When: December 18, 12-12:30 pm ET
Register at tinyurl.com/56959f62
The Centers for Medicare and Medicaid Services (#CMS) recently released the maximum fair prices (#MFP) for the 15 #IPAY 2027 drugs. How closely do they align with value-based prices?
New CEVR research found wide variation, which sends muddled signals to drugmakers about value.
tinyurl.com/3jsuybc7
New CEVR research found wide variation, which sends muddled signals to drugmakers about value.
tinyurl.com/3jsuybc7
Do Medicare’s IPAY 2027 Negotiated Drug Prices Reflect Value For Money? | Health Affairs Forefront
Examining whether negotiated prices align with value is one way of asking if CMS “got pricing right” and if the Medicare program is getting its money’s worth.
tinyurl.com
December 11, 2025 at 1:32 PM
The Centers for Medicare and Medicaid Services (#CMS) recently released the maximum fair prices (#MFP) for the 15 #IPAY 2027 drugs. How closely do they align with value-based prices?
New CEVR research found wide variation, which sends muddled signals to drugmakers about value.
tinyurl.com/3jsuybc7
New CEVR research found wide variation, which sends muddled signals to drugmakers about value.
tinyurl.com/3jsuybc7
Reposted by CEVR
Excited to announce 1st paper in new Health Affairs Scholar Series #HAS @Health_Affairs by @TuftsCEVR. For almost 20 years, CEVR has been leader on issues pertaining to value, cost-effectiveness, and risk tradeoffs in health care decisions. Watch for more! academic.oup.com/healthaffair...
The unintended consequences of the inflation reduction act on biosimilar market incentives and Medicare savings
AbstractIntroduction. The Inflation Reduction Act (IRA) authorizes Medicare price negotiation but includes a “special rule” deferring negotiation for biolo
academic.oup.com
December 9, 2025 at 8:02 PM
Excited to announce 1st paper in new Health Affairs Scholar Series #HAS @Health_Affairs by @TuftsCEVR. For almost 20 years, CEVR has been leader on issues pertaining to value, cost-effectiveness, and risk tradeoffs in health care decisions. Watch for more! academic.oup.com/healthaffair...
Some drugmakers are rolling out “pharm-to-table” programs to sell drugs directly to patients at lower costs, but how much will these programs to improve access and price transparency?
Read CEVR’s commentary on the promises and pitfalls of these programs.
tinyurl.com/mrv8dczp
Read CEVR’s commentary on the promises and pitfalls of these programs.
tinyurl.com/mrv8dczp
The ‘Pharm-To-Table’ Movement For Prescription Drugs: Promising Or Performative? | Health Affairs Forefront
Direct-to-patient programs offer a glimpse of an alternative future in which the consumer or the employer is brought closer to the manufacturer of the medicine prescribed.
tinyurl.com
December 5, 2025 at 3:55 PM
Some drugmakers are rolling out “pharm-to-table” programs to sell drugs directly to patients at lower costs, but how much will these programs to improve access and price transparency?
Read CEVR’s commentary on the promises and pitfalls of these programs.
tinyurl.com/mrv8dczp
Read CEVR’s commentary on the promises and pitfalls of these programs.
tinyurl.com/mrv8dczp
Did you publish a #CEA in 2025? Applications are now open for the 8th annual Tufts-CEVR CEA Paper of the Year Award.
Est. application time: <5 mins
Award: $500
Due: January 15th: forms.gle/hiPo3nYSE8rV...
#HEOR #healthecon #HTA
Est. application time: <5 mins
Award: $500
Due: January 15th: forms.gle/hiPo3nYSE8rV...
#HEOR #healthecon #HTA
Tufts-CEVR’s 8th Annual Cost-Effectiveness Analysis Paper of the Year Award
The submission deadline is January 15th, 2026. Click next to proceed.
forms.gle
December 3, 2025 at 7:15 PM
Did you publish a #CEA in 2025? Applications are now open for the 8th annual Tufts-CEVR CEA Paper of the Year Award.
Est. application time: <5 mins
Award: $500
Due: January 15th: forms.gle/hiPo3nYSE8rV...
#HEOR #healthecon #HTA
Est. application time: <5 mins
Award: $500
Due: January 15th: forms.gle/hiPo3nYSE8rV...
#HEOR #healthecon #HTA
Only 25% of cost-effectiveness analyses published from 2013-23 (n=7,800) omit societal costs (productivity, caregiving, travel, etc.), despite consensus guidelines recommending their inclusion.
Read at tinyurl.com/3htu3zn9
Read at tinyurl.com/3htu3zn9
Sage Journals: Discover world-class research
Subscription and open access journals from Sage, the world's leading independent academic publisher.
tinyurl.com
December 1, 2025 at 3:57 PM
Only 25% of cost-effectiveness analyses published from 2013-23 (n=7,800) omit societal costs (productivity, caregiving, travel, etc.), despite consensus guidelines recommending their inclusion.
Read at tinyurl.com/3htu3zn9
Read at tinyurl.com/3htu3zn9
The Inflation Reduction Act (#IRA) allows #Medicare to defer negotiation for drugs with expected biosimilar competition within 2 years of selection, but this provision may unintentionally reduce long-term savings according to new research from CEVR.
More at: tinyurl.com/nptjvxzb
More at: tinyurl.com/nptjvxzb
tinyurl.com
November 24, 2025 at 5:28 PM
The Inflation Reduction Act (#IRA) allows #Medicare to defer negotiation for drugs with expected biosimilar competition within 2 years of selection, but this provision may unintentionally reduce long-term savings according to new research from CEVR.
More at: tinyurl.com/nptjvxzb
More at: tinyurl.com/nptjvxzb
Rapid genome sequencing performed early in a hospitalization can save ~$160k for critically ill infants with suspected genetic conditions- but most US insurers do not cover it.
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Rapid Genome Sequencing Compared with a Gene Panel in Critically Ill Infants with a Suspected Genetic Disorder: An Economic Evaluation
To compare 1-year healthcare costs and quality-adjusted life years (QALYs) for two
diagnostic strategies in critically ill infants with suspected genetic disorders:
1) early rapid genome sequencing (w...
tinyurl.com
November 10, 2025 at 6:05 PM
Rapid genome sequencing performed early in a hospitalization can save ~$160k for critically ill infants with suspected genetic conditions- but most US insurers do not cover it.
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Read more about this new Tufts Medical Center research: tinyurl.com/yc7mmxs7
Come see CEVR's faculty at ISPOR Europe 2025 in Glasgow, Scotland.
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
CEVR Participation at ISPOR EU 2025 - Center for the Evaluation of Value and Risk in Health
tinyurl.com
November 4, 2025 at 7:17 PM
Come see CEVR's faculty at ISPOR Europe 2025 in Glasgow, Scotland.
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
Details of our speaking engagements can be found at tinyurl.com/4em5ak2t
#ISPOREurope
Join CEVR on Nov. 5 from 2:30-3:30 pm ET for a health policy seminar from Boshen Jiao, PhD, MPH. Dr. Jiao will discuss the inclusion of productivity, informal caregiving time, and future unrelated medical costs in economic evaluations.
More at: tinyurl.com/4ru3pmd8
More at: tinyurl.com/4ru3pmd8
CEVR Health Policy Seminar with Boshen Jiao, PhD, MPH - Center for the Evaluation of Value and Risk in Health
tinyurl.com
October 24, 2025 at 6:47 PM
Join CEVR on Nov. 5 from 2:30-3:30 pm ET for a health policy seminar from Boshen Jiao, PhD, MPH. Dr. Jiao will discuss the inclusion of productivity, informal caregiving time, and future unrelated medical costs in economic evaluations.
More at: tinyurl.com/4ru3pmd8
More at: tinyurl.com/4ru3pmd8
CEAs of SMA treatments frequently omit the effects of bereavement on caregivers, potentially undervaluing these interventions. Our new survey of bereaved parents better quantifies their experience of grief to inform future CEAs.
Read more at: tinyurl.com/2mcs6taa
Read more at: tinyurl.com/2mcs6taa
tinyurl.com
October 21, 2025 at 6:45 PM
CEAs of SMA treatments frequently omit the effects of bereavement on caregivers, potentially undervaluing these interventions. Our new survey of bereaved parents better quantifies their experience of grief to inform future CEAs.
Read more at: tinyurl.com/2mcs6taa
Read more at: tinyurl.com/2mcs6taa
The death of a child with SMA is a life-changing experience for parents, impacting their outlook on life, health, relationships, employment. New qualitative research explores the impacts of grief and strategies that help bereaved parents manage the loss of their child.
Read: tinyurl.com/mw2s2ezw
Read: tinyurl.com/mw2s2ezw
tinyurl.com
October 20, 2025 at 2:23 PM
The death of a child with SMA is a life-changing experience for parents, impacting their outlook on life, health, relationships, employment. New qualitative research explores the impacts of grief and strategies that help bereaved parents manage the loss of their child.
Read: tinyurl.com/mw2s2ezw
Read: tinyurl.com/mw2s2ezw
Going to AMCP 2025? Come see presentations by @mollytoba.bsky.social, Daniel Enright, and Angela Lin of CEVR's SPEC Team!
#AMCPNexus
#AMCPNexus
October 13, 2025 at 2:01 PM
Going to AMCP 2025? Come see presentations by @mollytoba.bsky.social, Daniel Enright, and Angela Lin of CEVR's SPEC Team!
#AMCPNexus
#AMCPNexus
US commercial payers vary in how they cover cell and gene therapies, according to a new study of 541 coverage policies by Tufts-CEVR’s SPEC team. 52% of policies had restrictions beyond FDA label, often limiting access to patient subgroups or requiring step therapy.
Read at: tinyurl.com/5dwhv726
Read at: tinyurl.com/5dwhv726
Variation in US Commercial Health Plan Coverage Restrictions for Cell and Gene Therapies
This Viewpoint examines variations in US commercial health plan coverage restrictions for cell and gene therapies.
tinyurl.com
September 30, 2025 at 7:16 PM
US commercial payers vary in how they cover cell and gene therapies, according to a new study of 541 coverage policies by Tufts-CEVR’s SPEC team. 52% of policies had restrictions beyond FDA label, often limiting access to patient subgroups or requiring step therapy.
Read at: tinyurl.com/5dwhv726
Read at: tinyurl.com/5dwhv726
CEAs often undervalue vaccines by excluding family spillover effects. New research from CEVR and Merck explores the impact of omissions.
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
tinyurl.com
September 22, 2025 at 5:46 PM
CEAs often undervalue vaccines by excluding family spillover effects. New research from CEVR and Merck explores the impact of omissions.
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
Half of studied CEAs omitted spillover effects. Including them improved cost-eff. by avg. of ~20%; 10% of results became cost-saving.
Read: tinyurl.com/y8p6jtwm
Older adults with dementia face substantial OOP costs. New CEVR research explores financial risks to patients/families: 21% of individuals w/ severe dementia face catastrophic costs; 12% fall below poverty threshold due to costs.
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Characterizing financial risk from out‐of‐pocket expenditures across dementia stages
INTRODUCTION Older adults with dementia incur considerable out-of-pocket (OOP) health care expenses, but it is unclear how their financial burden differs by dementia stage. METHODS We identified 2...
tinyurl.com
September 17, 2025 at 5:02 PM
Older adults with dementia face substantial OOP costs. New CEVR research explores financial risks to patients/families: 21% of individuals w/ severe dementia face catastrophic costs; 12% fall below poverty threshold due to costs.
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Read at: tinyurl.com/3pfbt7fp
@pattysynnott.bsky.social
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss new research to standardize definitions and outcomes reporting for patient-facing digital health interventions (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
CEVR Health Policy Seminar with Carl Asche, PhD, MSc - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
September 3, 2025 at 7:26 PM
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss new research to standardize definitions and outcomes reporting for patient-facing digital health interventions (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss his work to define patient-facing digital health interventions and standardize reporting practices (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp
CEVR Health Policy Seminar with Carl Asche, PhD, MSc - Center for the Evaluation of Value and Risk in Health
cevr.tuftsmedicalcenter.org
September 3, 2025 at 7:02 PM
Join CEVR on Sept. 30 from 2-3 pm ET for a health policy seminar from Carl Asche, PhD, MSc. Dr. Asche will discuss his work to define patient-facing digital health interventions and standardize reporting practices (PICOTS-ComTeC and CHEERS-DHI)
More at: tinyurl.com/ywn7abjp
More at: tinyurl.com/ywn7abjp